Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

610.60INR
10:36am BST
Change (% chg)

Rs10.45 (+1.74%)
Prev Close
Rs600.15
Open
Rs603.00
Day's High
Rs623.00
Day's Low
Rs603.00
Volume
1,641,741
Avg. Vol
927,120
52-wk High
Rs654.95
52-wk Low
Rs493.50

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Says Partner Elite Pharmaceuticals Got USFDA Nod For Methadone Hydrochloride Tablets
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Glenmark Pharmaceuticals Ltd ::PARTNER ELITE PHARMACEUTICALS RECEIVED APPROVAL FROM USFDA FOR METHADONE HYDROCHLORIDE 5 MG AND 10 MG TABLETS.METHADONE IS INDICATED FOR MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND--CLOCK LONG-TERM OPIOID TREATMENT.  Full Article

Glenmark Pharmaceuticals And Harbour Biomed Sign Agreement For Greater China To Develop GBR 1302
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS GLENMARK PHARMACEUTICALS AND HARBOUR BIOMED SIGN AGREEMENT FOR GREATER CHINA TO DEVELOP GBR 1302.SAYS CO WILL GET UPFRONT PAYMENT; ELIGIBLE TO GET PAYMENTS FOR ACHIEVING PRE-SPECIFIED DEVELOPMENT, REGULATORY MILESTONES.  Full Article

Glenmark Pharma Gets ANDA Approval For Cholesterol Drug For Oral Suspension
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS -GETS ANDA APPROVAL FOR COLESEVELAM HYDROCHLORIDE FOR ORAL SUSPENSION, 1.875 GRAMS/PACKET AND 3.75 GRAMS/PACKET.  Full Article

Glenmark Pharmaceuticals Unit Enters Licensing Deal With Seqirus
Friday, 6 Jul 2018 

July 6 (Reuters) - Glenmark Pharmaceuticals Ltd ::LICENSING DEAL WITH SEQIRUS FOR INVESTIGATIONAL SEASONAL ALLERGIC RHINITIS NASAL SPRAY FOR AUSTRALIA AND NEW ZEALAND.GLENMARK TO BE RESPONSIBLE FOR PRODUCT SUPPLY AND SEQIRUS FOR REGULATORY FILING AND COMMERCIALIZATION.GLENMARK WILL RECEIVE AN UPFRONT PAYMENT AS WELL AS REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FROM SEQIRUS.  Full Article

FDA Approves First sANDA For Glenmark Pharma's Manufacturing Facility In Monroe
Monday, 18 Jun 2018 

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::THE US FDA APPROVES FIRST SUPPLEMENTAL ABBREVIATED NEW DRUG APPLICATION (SANDA) FOR GLENMARK PHARMACEUTICALS' MANUFACTURING FACILITY IN MONROE, NORTH CAROLINA.GLENMARK PHARMA - APPROVAL COVERS ATOVAQUONE & PROGUANIL HYDROCHLORIDE TABLETS, 250 MG/100 MG AND 62.5 MG/25 MG.  Full Article

Glenmark Pharmaceuticals Announces First New Drug Application Submission For Ryaltris
Tuesday, 22 May 2018 

May 22 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS - ANNOUNCES CO'S FIRST NEW DRUG APPLICATION SUBMISSION FOR RYALTRIS FOR PATIENTS WITH SEASONAL ALLERGIC RHINITIS.GLENMARK PHARMACEUTICALS - EXPECTS THE FDA WILL DETERMINE WHETHER THE NDA IS COMPLETE FOR FILING WITHIN 60 DAYS.  Full Article

Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris
Monday, 21 May 2018 

May 21 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS - SUBMITTED NDA TO U.S. FDA FOR LEADING RESPIRATORY PIPELINE CANDIDATE RYALTRIS.  Full Article

Glenmark Pharma Gets ANDA Approval For Colesevelam Hydrochloride Tablets, 625 Mg
Monday, 21 May 2018 

May 21 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS CO GETS ANDA APPROVAL FOR COLESEVELAM HYDROCHLORIDE TABLETS, 625 MG.GLENMARK PHARMACEUTICALS LTD <<>> SAYS CO HAS ALREADY COMMENCED SUPPLIES OF THE PRODUCT TO THE U.S. MARKET.  Full Article

Glenmark Pharmaceuticals Says GBR 830 Phase 2A Study Completed
Friday, 18 May 2018 

May 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::GBR 830 PHASE 2A STUDY COMPLETED; ENROLLMENT FOR A PHASE 2B STUDY IN AD EXPECTED TO BEGIN IN JUNE 2018.  Full Article

Glenmark Pharma Says Grant Of Substitution And Launch Of Generic Seretide Accuhaler In Denmark
Wednesday, 16 May 2018 

May 16 (Reuters) - Glenmark Pharmaceuticals Ltd ::GRANT OF SUBSTITUTION AND SUCCESSFUL LAUNCH OF GENERIC SERETIDE ACCUHALER IN DENMARK.  Full Article